Open Collections

UBC Faculty Research and Publications

Selective COX-2 inhibitors : Are they safer than NSAIDs? Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 39 adds new evidence to information previously published about NSAIDs in Therapeutics Letters 4 and Letter 17. It also responds to our commitment in Therapeutics Letter 31 to report on celecoxib when published trials became available. Conclusions: Patients on rofecoxib had less complicated and symptomatic ulcers but more myocardial infarctions than patients on naproxen. COX-2 selective NSAIDs were associated with the same incidence of serious adverse events as non-selective NSAIDs. Celecoxib and meloxicam caused fewer withdrawals due to adverse events than non-selective NSAIDs. Head-to-head RCTs comparing NSAIDS with dosing regimens to optimize efficacy and safety would be useful.

Item Metadata

Title
Selective COX-2 inhibitors : Are they safer than NSAIDs?
Alternate Title
Therapeutics Letter 39
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2001-02
Description
Therapeutics Letter 39 adds new evidence to information previously published about NSAIDs in Therapeutics Letters 4 and Letter 17. It also responds to our commitment in Therapeutics Letter 31 to report on celecoxib when published trials became available. Conclusions: Patients on rofecoxib had less complicated and symptomatic ulcers but more myocardial infarctions than patients on naproxen. COX-2 selective NSAIDs were associated with the same incidence of serious adverse events as non-selective NSAIDs. Celecoxib and meloxicam caused fewer withdrawals due to adverse events than non-selective NSAIDs. Head-to-head RCTs comparing NSAIDS with dosing regimens to optimize efficacy and safety would be useful.
Subject
Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Meloxicam; Naproxen; Rofecoxib
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433618
URI
http://hdl.handle.net/2429/85028
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International